Skip to main content

Table 1 Characteristics of RA patients and healthy controls

From: Serum a proliferation-inducing ligand and MicroRNA-223 are associated with rheumatoid arthritis: diagnostic and prognostic implications

Parameter RA patients (n = 120) Healthy controls (n = 130) P value
Sex    0.13
 Male, n (%) 12 (10%) 22 (17%)  
 Female, n (%) 108 (90%) 108 (83%)  
Age (years) 38.25 ± 10.13 39.9 ± 15.2 0.32
Range (19–60) (20–59)  
Hemoglobin (g/dl) 11.83 ± 1.63 12.3 ± 2.5 0.08
Total leukocyte count (× 103/mm3) 7.72 ± 2.48 8 ± 3.1 0.43
Platelet count (×103/mm3) 279.6 ± 80.85 288.26 ± 75.2 0.4
ALT (U/l) 25.63 ± 10.89 27.51 ± 11.48 0.19
Creatinine (mg/dl) 0.82 ± 0.22 0.9 ± 0.42 0.06
Disease duration (y) 6.22 ± 4.45 NA  
MS (min) 25.38 ± 25.18 NA  
ESR (mm) 39.13 ± 23.6 NA  
RF, n (%)   NA  
 Positive 90 (75)   
 Negative 30 (25)   
ANA, n (%)   NA  
 Positive 18 (15)   
 Negative 102 (85)   
DAS28-CRP 2.98 ± 1.73 NA  
Remission < 2.3 48 (40)   
Low disease activity 2.3–2.7 9 (7.5)   
Mild disease activity 2.7–4.1 30 (25)   
High disease activity > 4.1 33 (27.5)   
VAS (mm) 5.22 ± 3.34 NA  
Swollen joint count (SJC) 5.33 ± 5.66 NA  
Tender joint count (TJC) 5.17 ± 5.45 NA  
Arthritis, n (%)   NA  
 Severe 87 (72.5)   
 Mild 33 (27.5)   
Deformities, n (%)   NA  
 Yes 84 (70)   
 No 36 (30)   
Fever, n (%)
 Yes 15 (12.5)   
 No 105 (87.5) NA  
Subcutaneous nodules, n (%)
 Yes 30 (25)   
 No 90 (75)   
Extra articular manifestations, n (%)   NA  
 Yes 24 (20)   
 No 96 (80)   
Treatment NA   
Steroids only 6 (5)   
MTX only 60 (50)   
HQN only 6 (5)   
MTX + HQN 24 (20)   
MTX + steroids 24 (20)   
  1. Data are expressed by mean ± SD or number (percentage). ALT alanine aminotransferase, ANA antinuclear antibody, CRP C-reactive protein, DAS28 28-Joint disease activity score, ESR erythrocyte sedimentation rate, HQN hydroquinone, MS morning stiffness, MTX methotrexate, NA not applicable, RF rheumatoid factor, VAS visual analogue scale for general health